NCT06502249View on ClinicalTrials.gov

Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

Not yet recruitingOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

September 30, 2028

Conditions

Lung CancerNSCLC

Trial Locations (1)

11566

Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab, Cairo

All Listed Sponsors

lead

Ain Shams University

OTHER